Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Breast Neoplasms 4Neoplasms 3Neoplasm Metastasis 2Triple Negative Breast Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Malignant Solid Tumour 1Leukemia, Myeloid, Acute 1Hamartoma Syndrome, Multiple 1Glioblastoma 1Castration-resistant Prostate Cancer 1Carcinoma, Renal Cell 1Breast Diseases 1Brain Neoplasms 1Advanced Solid Tumor 1

Interventions

Temozolomide 107Radiotherapy 60Radiation 28Bevacizumab 19Magnetic Resonance Spectroscopy 16Nivolumab 15Surgical Procedures, Operative 12Irinotecan 11Cyclophosphamide 10Specimen Handling 9Chemotherapy, Adjuvant 9Radiotherapy, Intensity-Modulated 8Radiosurgery 8O(6)-benzylguanine 8Carmustine 8poly ICLC 7pembrolizumab 7motexafin gadolinium 7fludarabine 7Leukapheresis 7Flucytosine 7sargramostim 6Radiotherapy, Conformal 6Erlotinib Hydrochloride 6Lomustine 5Ipilimumab 5Imiquimod 5Imatinib Mesylate 5Hydroxyurea 5Granulocyte-Macrophage Colony-Stimulating Factor 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Glioblastoma × dactolisib × Clear all
NCT01508104 2017-08-23

Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors

University of Cincinnati

Phase 1 Terminated
19 enrolled
CNSEndocrineNET

Brain Neoplasms, Glioblastoma, Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡